Infliximab and Methotrexate in Ankylosing Spondylitis
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
There is a great individual variability of pharmacokinetic of infliximab in patients treated
for ankylosing spondylitis (AS). Moreover, some patients have a treatment with methotrexate
(MTX), others have not.
Thus, the aim of this study is to assess the effect of MTX on the pharmacokinetic properties
of infliximab in 30 patients treated for AS, 15 with MTX, 15 without.